Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives

Cucchiara, Federico; Petrini, Iacopo; Romei, Chiara; Crucitta, Stefania; Lucchesi, M; Valleggi, Simona; Scavone, Cristina; Capuano, Annalisa; Liperi, Annalisa De; Chella, Antonio; Danesi, Romano; Re, Marzia Del

doi:10.1016/j.phrs.2021.105643

Cited by 16 publications

(18 citation statements)

References 198 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mathematical modelling can be combined with GFAP liquid biopsy results alongside other clinical data, such as scans, histological data and molecular profiling, to provide clinical insight. Integrating liquid biopsy with other clinical techniques could allow early detection and diagnosis for personalized precision treatment [ 55 , 56 ]. To be useful in the clinic, these must be combined in an accessible way.…”

Section: Discussionmentioning

confidence: 99%

Liquid biopsies for early diagnosis of brain tumours: in silico mathematical biomarker modelling

Blee

Liu

Harland

et al. 2022

J. R. Soc. Interface.

View full text Add to dashboard Cite

Brain tumours are the biggest cancer killer in those under 40 and reduce life expectancy more than any other cancer. Blood-based liquid biopsies may aid early diagnosis, prediction and prognosis for brain tumours. It remains unclear whether known blood-based biomarkers, such as glial fibrillary acidic protein (GFAP), have the required sensitivity and selectivity. We have developed a novel in silico model which can be used to assess and compare blood-based liquid biopsies. We focused on GFAP, a putative biomarker for astrocytic tumours and glioblastoma multi-formes (GBMs). In silico modelling was paired with experimental measurement of cell GFAP concentrations and used to predict the tumour volumes and identify key parameters which limit detection. The average GBM volumes of 449 patients at Leeds Teaching Hospitals NHS Trust were also measured and used as a benchmark. Our model predicts that the currently proposed GFAP threshold of 0.12 ng ml −1 may not be suitable for early detection of GBMs, but that lower thresholds may be used. We found that the levels of GFAP in the blood are related to tumour characteristics, such as vasculature damage and rate of necrosis, which are biological markers of tumour aggressiveness. We also demonstrate how these models could be used to provide clinical insight.

show abstract

Section: Discussionmentioning

confidence: 99%

Liquid biopsies for early diagnosis of brain tumours: in silico mathematical biomarker modelling

Blee

Liu

Harland

et al. 2022

J. R. Soc. Interface.

View full text Add to dashboard Cite

show abstract

“…Therefore, the role of the liquid biopsy to longitudinally monitor patients during treatment and to detect the minimal residual disease is under investigation and validation. Moreover, novel tools integrating different techniques combined together through artificial intelligence algorithms are in development, and, in this scenario, novel minimally invasive techniques such as liquid biopsy and radiomics may be successfully integrated [340][341][342][343].…”

Section: Real Time Follow Up Of Tumor Landscapes: the Rise Of The Liq...mentioning

confidence: 99%

EGFR signaling pathway as therapeutic target in human cancers

Maroni

Tenen

2022

Seminars in Cancer Biology

Self Cite

133

View full text Add to dashboard Cite

“…For example, liquid biopsy enables the analysis of molecules or macrostructures in low concentration from body liquid that shows minimal invasiveness towards patients who are susceptible to tumor or cannot withstand biopsy. Cucchiara et al integrated liquid biopsy and radiomics to monitor clonal heterogeneity of EGFR-Positive NSCLC (140). As a result, more individualized treatment plans can be tailored and patients with imperceptible premalignant lesions or who undergo surgery can also benefit, though the expense is another problem to be discussed.…”

Section: Further Developments In Brain Tumormentioning

confidence: 99%

“…Cucchiara et al. integrated liquid biopsy and radiomics to monitor clonal heterogeneity of EGFR -Positive NSCLC ( 140 ). As a result, more individualized treatment plans can be tailored and patients with imperceptible premalignant lesions or who undergo surgery can also benefit, though the expense is another problem to be discussed.…”

Section: Further Developments In Brain Tumormentioning

confidence: 99%

Current Advances and Challenges in Radiomics of Brain Tumors

Long

Zeng

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Imaging diagnosis is crucial for early detection and monitoring of brain tumors. Radiomics enable the extraction of a large mass of quantitative features from complex clinical imaging arrays, and then transform them into high-dimensional data which can subsequently be mined to find their relevance with the tumor’s histological features, which reflect underlying genetic mutations and malignancy, along with grade, progression, therapeutic effect, or even overall survival (OS). Compared to traditional brain imaging, radiomics provides quantitative information linked to meaningful biologic characteristics and application of deep learning which sheds light on the full automation of imaging diagnosis. Recent studies have shown that radiomics’ application is broad in identifying primary tumor, differential diagnosis, grading, evaluation of mutation status and aggression, prediction of treatment response and recurrence in pituitary tumors, gliomas, and brain metastases. In this descriptive review, besides establishing a general understanding among protocols, results, and clinical significance of these studies, we further discuss the current limitations along with future development of radiomics.

show abstract

Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives

Cited by 16 publications

References 198 publications

Liquid biopsies for early diagnosis of brain tumours: in silico mathematical biomarker modelling

Liquid biopsies for early diagnosis of brain tumours: in silico mathematical biomarker modelling

EGFR signaling pathway as therapeutic target in human cancers

Current Advances and Challenges in Radiomics of Brain Tumors

Contact Info

Product

Resources

About